

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: RAJU, et al. : Confirmation No.: 2915
APPLICATION NO.: 10/617,616 : Examiner: S. LOEWE
FILING DATE: July 11, 2003 : Group Art Unit: 1626
TITLE: N-HYDROXYAMIDE DERIVATIVES :
POSSESSING ANTIBACTERIALS ACTIVITY

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

The Office notified Applicants that a few references were not considered in Applicants' March 11, 2004 information disclosure statement. (See May 15, 2008 Office Action). Specifically, the Office has indicated that crossed-out references were not considered because copies were not provided. Accordingly, Applicants submit a Supplemental Information Disclosure Statement and PTO-1449 form with copies of the crossed-out references in addition to a few additional references.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: September 15, 2008

/Christian Smolizza/
Christian M. Smolizza
Attorney for Applicant(s)
Reg. No. 46,319

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733 -9094